 |
|
Symptomatic Improvement of Premenstrual Dysphoric Disorder With Sertraline TreatmentA Randomized Controlled Trial
Kimberly A. Yonkers, MD;
Uriel Halbreich, MD;
Ellen Freeman, PhD;
Candace Brown, PharmD;
Jean Endicott, PhD;
Ellen Frank, PhD;
Barbara Parry, MD;
Teri Pearlstein, MD;
Sally Severino, MD;
Anna Stout, PhD;
Andrea Stone, MD;
Wilma Harrison, MD
JAMA. 1997;278(12):983-988.
Abstract
| |
Context.
—Premenstrual dysphoric disorder is an important cause of symptoms and functional impairment in menstruating women.
Objective.
—To evaluate the efficacy of sertraline hydrochloride for treatment of premenstrual dysphoria by measuring changes in symptom expression and functional impairment.
Design.
—Two screening cycles followed by 1 single-blind placebo cycle and 3 cycles of randomized, double-blind, placebo treatment.
Setting.
—Twelve university-affiliated outpatient psychiatry and gynecology clinics.
Patients.
—Of the 447 women who requested participation, 243 met criteria for premenstrual dysphoric disorder and were randomized; 200 women completed the study.
Intervention.
—A flexible (50-150 mg) daily dose of sertraline hydrochloride.
Main Outcome Measures.
—The Daily Record of Severity of Problems, Hamilton Rating Scale for Depression, Clinical Global Impression Scale, and Social Adjustment Scale.
Results.
—Mean (±SD) total daily symptom scores decreased significantly (P<.001) in the sertraline-treated (64±22 to 44±19) compared with the placebotreated (62±22 to 54±24) groups. Significant improvement (P<.05) was found for all clinically derived symptom clusters (depressive, physical, and anger/irritability symptoms). Hamilton Rating Scale for Depression scores decreased by 44% and 29% in the sertraline and placebo groups, respectively (P<.002). End-point global ratings showed much or very much improvement in 62% of the active treatment group and 34% of the placebo treatment group (P<.001). Reported functional impairment was substantial at baseline. Improvement in psychosocial functioning with treatment was similar to what is found in studies of major depression.
Conclusions.
—Sertraline was significantly better than placebo for treatment of premenstrual dysphoria as reflected by symptomatic improvement and change in reported functional impairment. Serotonin reuptake inhibitors such as sertraline are useful therapeutic options for women with premenstrual dysphoria.
Author Affiliations
for the Sertraline Premenstrual Dysphoric Collaborative Study Group
From the Departments of Psychiatry and Obstetrics and Gynecology, The University of Texas Southwestern Medical Center at Dallas (Dr Yonkers), University of Buffalo, Buffalo, NY (Dr Halbreich), and University of Pennsylvania, Philadelphia (Dr Freeman); Departments of Clinical Pharmacy and Psychiatry, University of Tennessee, Memphis (Dr Brown); Department of Research Assessment and Training, New York State Psychiatric Institute, New York (Dr Endicott); Departments of Psychiatry, Western Psychiatric Institute, Pittsburgh, Pa (Dr Frank), University of California, San Diego (Dr Parry), Brown University, Providence, RI (Dr Pearlstein), University of New Mexico Health Science Center, Albuquerque (Dr Severino), Duke University, Durham, NC (Dr Stout), and University of Massachusetts Medical Center, Worcester (Dr Stone); and Pfizer Inc, New York, NY (Dr Harrison).
Footnotes
Additional members of the Sertraline Premenstrual Dysphoric Collaborative Study Group appear at the end of this article.
Reprints: Kimberly A. Yonkers, MD, The University of Texas Southwestern Medical Center, St Paul Professional Bldg I, Suite 520, 5959 Harry Hines Blvd, Dallas, TX 75235.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Management Strategies for Premenstrual Syndrome/Premenstrual Dysphoric Disorder
Jarvis et al.
The Annals of Pharmacotherapy 2008;42:967-978.
ABSTRACT
| FULL TEXT
Quality-of-Life Impairment in Depressive and Anxiety Disorders
Rapaport et al.
Am. J. Psychiatry 2005;162:1171-1178.
ABSTRACT
| FULL TEXT
Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: A Double-Blind, Placebo-Controlled Trial
Cohen et al.
Psychosom. Med. 2004;66:707-713.
ABSTRACT
| FULL TEXT
Continuous or Intermittent Dosing With Sertraline for Patients With Severe Premenstrual Syndrome or Premenstrual Dysphoric Disorder
Freeman et al.
Am. J. Psychiatry 2004;161:343-351.
ABSTRACT
| FULL TEXT
Premenstrual Dysphoric Disorder
Grady-Weliky
NEJM 2003;348:433-438.
FULL TEXT
SSRIs for premenstrual dysphoric disorder
DTB 2002;40:70-72.
ABSTRACT
| FULL TEXT
Depression in Women across the Life Cycle
Moore and Emanuel
Journal of Pharmacy Practice 2001;14:511-525.
ABSTRACT
Differential Response to Antidepressants in Women With Premenstrual Syndrome/Premenstrual Dysphoric Disorder: A Randomized Controlled Trial
Freeman et al.
Arch Gen Psychiatry 1999;56:932-939.
ABSTRACT
| FULL TEXT
Characteristics of Placebo Responses in Medical Treatment of Premenstrual Syndrome
Freeman and Rickels
Am. J. Psychiatry 1999;156:1403-1408.
ABSTRACT
| FULL TEXT
Iatrogenic Acute Estrogen Deficiency and Psychiatric Syndromes in Breast Cancer Patients
Duffy et al.
Psychosomatics 1999;40:304-308.
ABSTRACT
| FULL TEXT
A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression
SOgaard et al.
J Psychopharmacol 1999;13:406-414.
ABSTRACT
Luteal Phase Sertraline Treatment for Premenstrual Dysphoric Disorder: Results of a Double-blind, Placebo-Controlled, Crossover Study
Jermain et al.
Arch Fam Med 1999;8:328-332.
ABSTRACT
| FULL TEXT
A 45-Year-Old Woman With Premenstrual Dysphoric Disorder
Parry
JAMA 1999;281:368-373.
FULL TEXT
Longitudinal Population-Based Twin Study of Retrospectively Reported Premenstrual Symptoms and Lifetime Major Depression
Kendler et al.
Am. J. Psychiatry 1998;155:1234-1240.
ABSTRACT
| FULL TEXT
Use of Serotonin Reuptake Inhibitors by Women of Childbearing Potential
Goldstein et al.
JAMA 1998;279:1873-1874.
FULL TEXT
Other articles noted
Evid. Based Ment. Health 1998;1:36-36.
FULL TEXT
Sertraline for Premenstrual Dysphoric Disorder
Cohen et al.
JAMA 1998;279:357-358.
FULL TEXT
Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life
Goodnick and Goldstein
J Psychopharmacol 1998;12:S21-S54.
ABSTRACT
Sertraline for PMDD
JWatch Psychiatry 1997;1997:9-9.
FULL TEXT
Sertraline: Relief for PMS?
JWatch Women's Health 1997;1997:18-18.
FULL TEXT
SERTRALINE FOR PREMENSTRUAL DYSPHORIC DISORDER
JWatch General 1997;1997:6-6.
FULL TEXT
Premenstrual Dysphoric Disorder What's That?
Gold
JAMA 1997;278:1024-1025.
ABSTRACT
|
